Colchicine USP Pharma Grade API is supplied as a crystalline active pharmaceutical ingredient intended for formulation into immediate-release tablets, hard gelatin capsules, oral granules, oral solutions, and injectable dosage forms. The material is assigned CAS 64-86-8, molecular formula C22H25NO6, and relative molecular mass 399.44. The manufacturer’s grade designations are COLC-USP-T/C for tablet and capsule pre-bulk, COLC-USP-G for granule feed, and COLC-USP-I/LY for injectable or lyophilized processing. These grades are differentiated by particle size distribution, residual solvent load, bioburden, and bacterial endotoxin specification. The API is used under medical direction for acute gout flares, prophylaxis of gout recurrence, familial Mediterranean fever, and selected pericarditis protocols; it is not a finished dose form and should not be confused with technical-grade colchicine, demecolcine, thiocolchicoside, or botanical extracts intended for laboratory use.

Because colchicine is a low-dose, narrow-therapeutic-index API, incoming bulk material cannot be released based solely on visual appearance. The manufacturer’s certificate of analysis includes identification by IR and HPLC, assay on the dried basis, related substances, water or loss on drying, residual solvent profile, and elemental impurity data. For injectable product, bacterial endotoxin and bioburden data are also required. A product described as USP Pharma Grade API for tablet/capsule/granule/injection is therefore not one material; it is a family of grade-controlled lots sharing the same compendial chemistry but with different physical and microbiological controls.

Which compendial parameters define the pharmaceutical suitability of Colchicine USP API for oral and injectable processing?

The USP monograph for colchicine establishes identity, assay, impurity, loss on drying, residual solvent, and elemental impurity boundaries. Assay by HPLC is calculated against a USP Colchicine Reference Standard and controlled within 97.0%–102.0% on the dried basis. Related substances are quantified by the same HPLC procedure; unspecified impurities are constrained by monograph limits, and reporting follows ICH Q3B with a reporting threshold of 0.10%. For injectable preparation, compendial chemical purity alone is insufficient; bacterial endotoxins are determined by the Limulus amebocyte lysate method in USP <85>, with the acceptance criterion derived from the parenteral K/M exposure calculation. Elemental impurities are evaluated according to ICH Q3D and USP <232>/<233>; the daily exposure limits for As, Pb, Cd, and Hg in parenteral administration are 15, 5, 2, and 3 µg/day, respectively. The finished product manufacturer must convert these daily exposure values to concentration limits using the maximum daily dose of colchicine. Identity is confirmed by infrared absorption and by HPLC retention time against the USP Colchicine RS; system suitability for HPLC requires resolution between colchicine and the nearest specified related substance peak.

For reversed-phase HPLC, a C18 column and UV detection near 350 nm are typical because the tropolone chromophore absorbs in that region. The mobile phase is usually acidic to suppress ionisation of the phenolic hydroxyl. If a botanical extraction route is used, the residual solvent profile may include ethanol/water or chlorinated extraction solvents; routine control follows USP <467> with ICH Q3C limits. Methylene chloride has a PDE of 6.0 mg/day, chloroform 0.6 mg/day, and ethyl acetate 50 mg/day. Elemental impurity risk from plant-derived material includes soil uptake of As, Cd, Hg, and Pb; therefore a supplier’s elemental impurity summary should not be limited to process catalysts alone.

Impurity control separates USP colchicine from technical-grade alkaloid preparations and thiocolchicoside-type derivatives

Technical-grade colchicine obtained for laboratory use is not manufactured under ICH Q7 GMP conditions and may contain variable quantities of related colchicine alkaloids, including demecolcine, colchiceine, β-lumicolchicine, and residual glycosidic precursors. Pharmaceutical-grade material is screened by HPLC against the USP Colchicine RS, and the extraction or synthesis route is selected to minimize late-eluting tropolone impurities. The API is not equivalent to thiocolchicoside or demecolcine; those molecules are structurally modified at the tropolone C-10 position and exhibit different pharmacopoeial monographs, retention times, IR spectra, and toxicological boundaries. A supplier declaration of alkaloid purity without a USP method designation, batch-specific HPLC chromatogram, and residual solvent statement is insufficient for GMP use. Published data on cross-reader reliability for botanical source impurity fingerprints is limited, but compendial identity and assay methods are designed to detect substitution or gross adulteration.

Physical storage and handling requirements distinguish pharmaceutical grade from less controlled material. Colchicine is supplied as a pale yellow crystalline powder that darkens on prolonged light exposure. Storage in hermetically sealed, light-resistant containers at controlled room temperature is required; the powder is not autoclaved before formulation unless the finished dosage form is terminally sterilized. Photostability data for colchicine in solution show decomposition, so supply chain packaging uses opaque double polyethylene liners within fiber drums. Alkaline conditions and temperatures above ambient accelerate degradation to colchiceine; therefore neutral or acidic processing is used in wet granulation and oral solution compounding.

Low-dose direct compression and granule layering equipment behavior

For tablet and capsule manufacturing, colchicine is typically presented as a low-dose active at 0.5 mg or 0.6 mg per unit. Direct compression is feasible only after the API is passed through a 500 µm mesh screen and triturated with lactose monohydrate or microcrystalline cellulose before final mixing. Without this step, electrostatic adhesion to blender surfaces and agglomerate formation can increase content uniformity failure beyond the USP <905> acceptance value. A production-scale bin blender or twin-shell V-blender can exhibit segregation of low-dose colchicine if the API particle size distribution is bimodal; wet granulation onto a starch binder or hydroalcoholic drug solution is preferred when the batch size exceeds 100 kg. The supplier may specify an oral-grade D90 ≤ 100 µm for solid-dosage pre-bulk; this is a manufacturer-specified value, not a compendial acceptance criterion. High-dose colchicine is not a standard term because the therapeutic index is narrow and dose strengths are low.

When the dosage form shifts from tablet to injectable, cleanroom and endotoxin constraints supersede oral particulate acceptance criteria

Injectable colchicine production requires a sterilizable starting material with low bioburden, reduced insoluble particle load, and an endotoxin limit calculated from the maximum parenteral dose. If the finished product is a solution, the API is dissolved in a filtered vehicle and passed through a 0.22 µm sterilizing filter before aseptic filling; the API itself is not dry-heat sterilized because thermolytic opening of the tropolone ring may reduce potency. Lyophilized formulations require the API to be dissolved, filtered, filled, and freeze-dried; the pre-lyophilization solution is protected from light to limit photochemical degradation. Bacterial endotoxin testing by USP <85> is performed on each injectable-grade lot, and the specification is derived from the K/M equation using K = 5 EU/kg for parenteral routes and M equal to the maximum bolus dose in kilograms; this normally corresponds to a practical acceptance criterion below 1.0 EU per mg when the product is used as a single-dose injection at low colchicine mass. Insoluble particulate controls for the finished injectable product follow USP <788>, while API particle issues are handled upstream by filtration or by selecting a particle size specification that does not exceed the filter capacity. Published data for this specific configuration is limited, so the injectable supplier specification must be justified from the finished product risk assessment under ICH Q9.

Colchicine oral granules and oral solutions are prepared using wet granulation or liquid layering because the API is freely soluble in water and alcohol. In high-shear granulation, the drug can be dissolved in the binder solution and sprayed onto mannitol or sucrose granules to avoid dry mixing of the low-dose active; granulation endpoint is monitored by impeller power consumption and product temperature. After drying in a fluid-bed dryer, the granules are sized through an 850 µm sieve and lubricated with magnesium stearate for capsule filling. In aqueous oral solution, light protection and pH control below neutral are required; the tropolone ring can undergo base-catalyzed hydrolysis to colchiceine, which is an identified impurity. The oral liquid is therefore compounded with a citric acid buffer to maintain pH between 3.0 and 4.0 and stored in amber glass bottles. Capsule filling with dosator-type machines requires a granule bulk density above 0.45 g/cm³ and flow function coefficient above 4 to maintain mass uniformity; if bulk density falls below this value, the dosator nozzle may underfill at speeds above 30 cycles/min. These parameters are verified by formulation trials because published data for this specific configuration is limited.

In the European market, the same API may be handled under the Ph. Eur. monograph for colchicine. Compendial methods are not always identical; differences in acceptance criteria for related substances and residual solvents require the manufacturer to perform a gap analysis between the USP and Ph. Eur. methods before the product is released into both regions. When the product is labeled only as USP grade, compliance with Ph. Eur. cannot be assumed unless a dual-monograph certificate is provided. This is a regulatory distinction relevant to multinational products.

Each lot of colchicine USP API is accompanied by a certificate of analysis that reports assay, impurity profile, loss on drying, residual solvents, elemental impurities, and, for injectable grade, bacterial endotoxin content. Incoming bulk material is handled under 21 CFR 211.84 and ICH Q7; identity, purity, and endotoxin release are completed before manufacture of the finished drug product. The absence of a compendial dissolution specification at the API stage means that formulation-specific dissolution testing must be performed on the finished tablet or capsule using USP <711> and the approved method in the drug product monograph. Materials stored beyond the supplier’s retest date require re-evaluation of assay and water content before use.